Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

February 28, 2020 1:46 AM UTC
Updated on Feb 28, 2020 at 1:51 AM UTC

Migraine drug marks Biohaven’s first FDA approval

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval. NURTEC ODT, a CGRP antagonist, is formulated as a quick-dissolving tablet. Biohaven gained $2.63 to $43.45 in after-hours trading...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article